Paradigm Therapeutics, a Mount Nice, SC-based biopharmaceutical firm, acquired an extra funding of $12.6M from Eshelman Ventures.
It introduced the entire funding in 2025 for Paradigm Therapeutics to $25.1M.
The corporate intends to make use of the funds to speed up actions related to the anticipated business launch of the SD-101 program globally, together with manufacturing and regulatory actions.
Led by CEO Robert Ryan, Paradigm Therapeutics is a privately held, clinical-stage pharmaceutical firm targeted on growing revolutionary therapies to handle vital medical wants within the remedy of uncommon illnesses. Its principal focus is the remedy of Epidermolysis Bullosa (EB). SD-101, its remedy for the remedy of pores and skin results in sufferers with Epidermolysis Bullosa, has accomplished Part II and Part III scientific trials. SD-101 is a topical cream that requires no particular dealing with and could be saved at room temperature and has demonstrated potential to supply enchancment in treating the extreme pores and skin results seen in sufferers throughout all EB subtypes.
FinSMEs
20/06/2025
